Market Research Logo

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Polycystic Ovarian Syndrome - Pipeline Review, H2 2016’, provides an overview of the Polycystic Ovarian Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
    • The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects
    • The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Polycystic Ovarian Syndrome Overview
    Therapeutics Development
    Pipeline Products for Polycystic Ovarian Syndrome - Overview
    Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis
    Polycystic Ovarian Syndrome - Therapeutics under Development by Companies
    Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes
    Polycystic Ovarian Syndrome - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Polycystic Ovarian Syndrome - Products under Development by Companies
    Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes
    Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
    Addex Therapeutics Ltd
    Crinetics Pharmaceuticals, Inc.
    EffRx Pharmaceuticals S.A.
    Euroscreen S.A.
    Merck KGaA
    Millendo Therapeutics, Inc.
    Vicore Pharma AB
    Polycystic Ovarian Syndrome - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    C-21 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    choriogonadotropin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ESN-364 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JDSCR-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KDT-501 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    metformin hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MLE-4901 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Polycystic Ovarian Syndrome - Dormant Projects
    Polycystic Ovarian Syndrome - Discontinued Products
    Polycystic Ovarian Syndrome - Product Development Milestones
    Featured News & Press Releases
    Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome
    Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome
    Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
    Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients
    Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364
    Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
    Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
    Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364
    Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
    Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016
    Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2016
    Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
    Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H2 2016
    Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H2 2016
    Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H2 2016
    Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics, Inc., H2 2016
    Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Polycystic Ovarian Syndrome - Dormant Projects, H2 2016
    Polycystic Ovarian Syndrome - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016
    Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report